Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: A single center analysis

We recruited 805 patients with suspicious pulmonary masses that were identified finally as lung cancer or benign pulmonary masses. The serum levels of four tumor markers, including squamous cell carcinoma antigen (SCC), carcinoembryonic antigen (CEA), cytokeratin 19 fragment antigen 21-1 (Cyfra21-1) and neuron specific enolase (NSE) were tested for every patient. Though receiver operating characteristic (ROC) curves indicated unsatisfactory diagnostic power of those four tumor markers for lung cancer, 37.3% of early-staged lung cancer could be diagnosed just on the combination assays of the four tumor markers, under adjusted cut-off values through our statistical analysis retrospectively.

[1]  G. Pelosi,et al.  Role of positron emission tomography scanning in the management of lung nodules detected at baseline computed tomography screening. , 2007, The Annals of thoracic surgery.

[2]  J. Mayo,et al.  Image-guided video-assisted thoracoscopic resection of small peripheral lung nodules. , 2005, Advances in surgery.

[3]  N. Viñolas,et al.  Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as Tumor Markers in Patients with Lung Cancer: Comparison with CYFRA 21-1, CEA, SCC and NSE , 2008, Tumor Biology.

[4]  N. Viñolas,et al.  Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report. , 1998, Anticancer research.

[5]  A. Heinecke,et al.  CYFRA 21-1 serum analysis in patients with esophageal cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  F. Guadagni,et al.  A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  B. Wieskopf,et al.  Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. , 1995, Chest.

[8]  L. Tanoue,et al.  The new lung cancer staging system. , 2009, Chest.

[9]  D. Niewoehner,et al.  Clinical utility of tumor markers in the management of non-small cell lung cancer. , 2003, Methods in molecular medicine.

[10]  K. Feldmann,et al.  Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer. , 2010, Anticancer research.

[11]  F. J. Podbielski,et al.  Percutaneous Biopsy in Evaluation of Lung Nodules , 2004, JSLS : Journal of the Society of Laparoendoscopic Surgeons.

[12]  F. Masa,et al.  Squamous cell carcinoma antigen (SCC Ag) in the diagnosis and prognosis of lung cancer. , 1994, Chest.

[13]  J Hilden,et al.  Regret graphs, diagnostic uncertainty and Youden's Index. , 1996, Statistics in medicine.

[14]  Chun-Liang Lai,et al.  Diagnostic value of Her‐2/neu, Cyfra 21‐1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma , 2010, Pathology.

[15]  M. Gould.  CT screening for lung cancer. , 2007, The New England journal of medicine.

[16]  Takashi Ohtsuka,et al.  Radiological examination for peripheral lung cancers and benign nodules less than 10 mm. , 2003, Lung cancer.

[17]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[18]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[19]  C. Roussos,et al.  Diagnostic and prognostic significance of squamous cell carcinoma antigen in non-small cell lung cancer. , 2001, Lung cancer.

[20]  G. Kenter,et al.  Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer. , 1997, Anticancer research.

[21]  J. Kulpa,et al.  Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. , 2002, Clinical chemistry.

[22]  C. Vidal,et al.  Tumor markers as prognostic factors in treated non-small cell lung cancer. , 2003, Anticancer research.

[23]  Y. Nagasaka,et al.  Assessment of serum CYFRA 21‐1 in lung cancer , 1996, Cancer.

[24]  Elisabeth Brambilla,et al.  The 2004 World Health Organization classification of lung tumors. , 2005, Seminars in roentgenology.

[25]  A. Gunduz,et al.  [Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study]. , 2010, Archivos de bronconeumologia.

[26]  I. O'Muircheartaigh,et al.  Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer. , 1997, The European respiratory journal.

[27]  H. Satoh,et al.  Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis. , 2010, Anticancer research.

[28]  Tetsuya Shimizu,et al.  Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer. , 2010, Anticancer research.

[29]  Xiong-zeng Zhu,et al.  Study of prognostic predictors for non-small cell lung cancer. , 1999, Lung cancer.

[30]  E. Felip,et al.  Diagnostic utility of CYFRA 21‐1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions , 1999, Cancer.

[31]  E. Odagiri.  [Neuron specific enolase (NSE)]. , 1999, Nihon rinsho. Japanese journal of clinical medicine.